Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 3-Hydroxyanthranilate oxygenase activity is increased in the brains of Huntington disease victims.

Literature DB >> 2967497

3-Hydroxyanthranilate oxygenase activity is increased in the brains of Huntington disease victims.

R Schwarcz¹, E Okuno, R J White, E D Bird, W O Whetsell.

Abstract

An excess of the tryptophan metabolite quinolinic acid in the brain has been hypothetically related to the pathogenesis of Huntington disease. Quinolinate's immediate biosynthetic enzyme, 3-hydroxyanthranilate oxygenase (EC 1.13.11.6), has now been detected in human brain tissue. The activity of 3-hydroxyanthranilate oxygenase is increased in Huntington disease brains as compared to control brains. The increment is particularly pronounced in the striatum, which is known to exhibit the most prominent nerve-cell loss in Huntington disease. Thus, the Huntington disease brain has a disproportionately high capability to produce the endogenous "excitotoxin" quinolinic acid. This finding may be of relevance for clinical, neuropathologic, and biochemical features associated with Huntington disease.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 1988 PMID： 2967497 PMCID： PMC280365 DOI： 10.1073/pnas.85.11.4079

Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN： 0027-8424 Impact factor: 11.205

27 in total

1. THE ENZYMATIC CONVERSION OF QUINOLINATE TO NICOTINIC ACID MONONUCLEOTIDE IN MAMMALIAN LIVER.

Authors: R K GHOLSON; I UEDA; N OGASAWARA; L M HENDERSON
Journal: J Biol Chem Date: 1964-04 Impact factor: 5.157

2. STUDIES ON THE BIOSYNTHESIS OF NICOTINAMIDE ADENINE DINUCLEOTIDE. I. ENZYMIC SYNTHESIS OF NIACIN RIBONUCLEOTIDES FROM 3-HYDROXYANTHRANILIC ACID IN MAMMALIAN TISSUES.

Authors: Y NISHIZUKA; O HAYAISHI
Journal: J Biol Chem Date: 1963-10 Impact factor: 5.157

3. Protein measurement with the Folin phenol reagent.

Authors: O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal: J Biol Chem Date: 1951-11 Impact factor: 5.157

4. Quinolinic acid metabolism; urinary excretion by the rat following tryptophan and 3-hydroxyanthranilic acid administration.

Authors: L M HENDERSON; H M HIRSCH
Journal: J Biol Chem Date: 1949-12 Impact factor: 5.157

5. Normal excretion of quinolinic acid in Huntington's disease.

Authors: M P Heyes; E S Garnett; R R Brown
Journal: Life Sci Date: 1985-11-11 Impact factor: 5.037

6. A radioenzymatic assay for quinolinic acid.

Authors: A C Foster; E Okuno; D S Brougher; R Schwarcz
Journal: Anal Biochem Date: 1986-10 Impact factor: 3.365

7. Excitotoxic models for neurodegenerative disorders.

Authors: R Schwarcz; A C Foster; E D French; W O Whetsell; C Köhler
Journal: Life Sci Date: 1984-07-02 Impact factor: 5.037

8. Rat 3-hydroxyanthranilic acid oxygenase: purification from the liver and immunocytochemical localization in the brain.

Authors: E Okuno; C Köhler; R Schwarcz
Journal: J Neurochem Date: 1987-09 Impact factor: 5.372

9. Homozygotes for Huntington's disease.

Authors: N S Wexler; A B Young; R E Tanzi; H Travers; S Starosta-Rubinstein; J B Penney; S R Snodgrass; I Shoulson; F Gomez; M A Ramos Arroyo
Journal: Nature Date: 1987 Mar 12-18 Impact factor: 49.962

10. Synthesis of quinolinic acid by 3-hydroxyanthranilic acid oxygenase in rat brain tissue in vitro.

Authors: A C Foster; R J White; R Schwarcz
Journal: J Neurochem Date: 1986-07 Impact factor: 5.372

34 in total

1. Dysfunctional kynurenine pathway metabolism in the R6/2 mouse model of Huntington's disease.

Authors: Korrapati V Sathyasaikumar; Erin K Stachowski; Laura Amori; Paolo Guidetti; Paul J Muchowski; Robert Schwarcz
Journal: J Neurochem Date: 2010-03-17 Impact factor: 5.372

2. Tryptophan 2,3-dioxygenase and indoleamine 2,3-dioxygenase 1 make separate, tissue-specific contributions to basal and inflammation-induced kynurenine pathway metabolism in mice.

Authors: Paul B Larkin; Korrapati V Sathyasaikumar; Francesca M Notarangelo; Hiroshi Funakoshi; Toshikazu Nakamura; Robert Schwarcz; Paul J Muchowski
Journal: Biochim Biophys Acta Date: 2016-07-05

3-Hydroxyanthranilate oxygenase activity is increased in the brains of Huntington disease victims.

1. THE ENZYMATIC CONVERSION OF QUINOLINATE TO NICOTINIC ACID MONONUCLEOTIDE IN MAMMALIAN LIVER.

2. STUDIES ON THE BIOSYNTHESIS OF NICOTINAMIDE ADENINE DINUCLEOTIDE. I. ENZYMIC SYNTHESIS OF NIACIN RIBONUCLEOTIDES FROM 3-HYDROXYANTHRANILIC ACID IN MAMMALIAN TISSUES.

3. Protein measurement with the Folin phenol reagent.

4. Quinolinic acid metabolism; urinary excretion by the rat following tryptophan and 3-hydroxyanthranilic acid administration.

5. Normal excretion of quinolinic acid in Huntington's disease.

6. A radioenzymatic assay for quinolinic acid.

7. Excitotoxic models for neurodegenerative disorders.

8. Rat 3-hydroxyanthranilic acid oxygenase: purification from the liver and immunocytochemical localization in the brain.

9. Homozygotes for Huntington's disease.

10. Synthesis of quinolinic acid by 3-hydroxyanthranilic acid oxygenase in rat brain tissue in vitro.

1. Dysfunctional kynurenine pathway metabolism in the R6/2 mouse model of Huntington's disease.

2. Tryptophan 2,3-dioxygenase and indoleamine 2,3-dioxygenase 1 make separate, tissue-specific contributions to basal and inflammation-induced kynurenine pathway metabolism in mice.

3. Regulation of quinolinic acid neosynthesis in mouse, rat and human brain by iron and iron chelators in vitro.

Review 4. Reactive oxygen/nitrogen species and their functional correlations in neurodegenerative diseases.

Review 5. The kynurenine pathway and the brain: Challenges, controversies and promises.

Review 6. A two-electron-shell game: intermediates of the extradiol-cleaving catechol dioxygenases.

7. Observing 3-hydroxyanthranilate-3,4-dioxygenase in action through a crystalline lens.

Review 8. Tryptophan, adenosine, neurodegeneration and neuroprotection.

Review 9. Kynurenines in chronic neurodegenerative disorders: future therapeutic strategies.

10. Steady-state kinetics and inhibition of anaerobically purified human homogentisate 1,2-dioxygenase.